Tag - merck

 
 

MERCK

Daiichi Sankyo is aiming for at least ¥900 billion of revenue from its oncology business in the fiscal year ending in March 2026.
BUSINESS
Oct 20, 2023
Merck signs $5.5 billion deal with Daiichi for cancer therapy development
Daiichi Sankyo is aiming for at least ¥900 billion of revenue from its oncology business in the fiscal year ending in March 2026.
Japan Times
WORLD / Science & Health
Jun 6, 2023
Cancer vaccines poised to unlock 'new treatment paradigm' with Merck-Moderna data
Scientists have been chasing the dream of vaccines to treat cancer for decades with few successes.
Japan Times
WORLD / Science & Health
Apr 17, 2023
Moderna-Merck cancer vaccine plus Keytruda delays recurrence of skin cancer
The findings of the recent trial suggest that adding a personalized cancer vaccine to antibody-based immunotherapy could prolong the time patients have without death or the cancer's return.
Japan Times
COMMENTARY / World
Jan 4, 2023
Cancer vaccine hunt finally makes progress
A small study shows promise in deploying mRNA technology against melanoma — but fighting tumors is vastly more complex than tackling COVID-19.
Japan Times
BUSINESS
Mar 15, 2022
Drugmakers pause trials in Russia while still sending medicine
Major pharmaceutical firms are seeking to strike a balance between international opprobrium over Russia's invasion of Ukraine and the needs of sick patients.
Japan Times
WORLD / Science & Health
Feb 1, 2022
How does Merck's COVID-19 pill compare to Pfizer's?
Pfizer said final trial results showed that its treatment reduced the chance of hospitalization or death by 89%, while Merck said their pill reduced those chances by 30%.
Japan Times
WORLD / Science & Health
Dec 24, 2021
Merck’s COVID-19 pill comes with warning for pregnant women
U.S. regulators cleared the drug for emergency use Thursday but said it is not recommended for use in pregnant people.
Japan Times
BUSINESS
Dec 17, 2021
Pfizer will dominate $20 billion COVID-19 pill market in 2022, analysis shows
Demand for the medications is poised to outpace supply as COVID-19 spreads around the globe and scientists question how well vaccines and antibody treatments will hold up against omicron.
Japan Times
WORLD
Nov 27, 2021
Merck says its antiviral pill is less effective in final analysis
A final analysis of a clinical trial said the antiviral pill reduced the risk of hospitalization and death among high-risk COVID patients by 30%, down from an earlier estimate of 50%.
Japan Times
JAPAN / Science & Health
Nov 10, 2021
Japan to pay $1.2 billion for 1.6 million courses of Merck's COVID-19 pill
Countries have rushed to sign deals to buy molnupiravir since data last month showed that when given early in the illness the drug could halve the chances of dying or being hospitalized.
Japan Times
COMMENTARY / World
Nov 7, 2021
COVID-19 drugs will change the way we live with the virus
New COVID-19 drug approvals couldn't be timelier as hospitals face massive backlogs of delayed procedures.
Japan Times
JAPAN / Explainer
Oct 20, 2021
Oral drug molnupiravir seen as 'trump card' in Japan's battle against COVID-19
The treatment developed by Merck could receive fast-track approval by the end of the year, and other oral drugs to fight the coronavirus are not far behind.
Japan Times
WORLD
Oct 14, 2021
Rush to buy Merck’s COVID-19 pill risks leaving poor countries behind
Despite efforts to license molnupiravir to generic-drug firms, the same risks of unequal distribution remain, says report.
Japan Times
JAPAN
Oct 4, 2021
Japan in talks to procure Merck oral drug for mild COVID-19 symptoms
Molnupiravir was seen to halve the likelihood of hospitalization or death, according to an interim analysis of clinical trials across areas including Japan, Europe and the U.S.
Japan Times
WORLD / Science & Health
Oct 2, 2021
Merck pill seen as 'huge advance,' raises hope of preventing COVID-19 deaths
An experimental antiviral pill developed by Merck & Co. could halve the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19.
Japan Times
BUSINESS / FOCUS
Jun 4, 2021
Chinese drugmakers take aim at lucrative U.S. anti-cancer market
In recent years, medicines that free the immune system to attack tumors have become blockbusters in a $150 billion global market.
Japan Times
WORLD / Science & Health
Jul 23, 2019
Congo health minister's resignation over Ebola snub could unblock new vaccine
Congo's health minister resigned on Monday after being stripped of responsibility for managing the country's Ebola outbreak, potentially paving the way for the introduction of a second vaccine to contain the spreading epidemic.
Japan Times
WORLD / Science & Health
Aug 6, 2018
Experimental Ebola vaccinations to begin Wednesday in eastern Congo
Vaccinations against a new outbreak of Ebola virus in eastern Democratic Republic of Congo are due to begin on Wednesday, a senior official at the health ministry said on Sunday.
BUSINESS / Companies
Mar 8, 2018
Japan's Eisai agrees with U.S.-based Merck on potential $5.76 billion cancer drugs deal
Eisai Co. and U.S.-based Merck & Co. said Thursday they have agreed to jointly develop cancer drugs for global sales, with the Japanese pharmaceutical firm potentially receiving up to $5.76 billion if it proves a success.
Japan Times
WORLD
Aug 15, 2017
After Merck chief quits, Under Armour CEO steps down from Trump's business council
Under Armour Inc.'s Kevin Plank became the latest chief executive to quit President Donald Trump's council of U.S. business leaders, as membership on the panel has become enmeshed in the country's volatile politics after violent riots in Virginia over the weekend.

Longform

Father's Day is said to have come to Japan around 1950, shortly after the establishment of Mother's Day.
The evolving nature of fatherhood in Japan